The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit
later.
We apologize for any inconvenience caused
Clinical study of rhIL-11 derivatives and rhIL-11 in the treatment of chemotherapy-induced thrombo-cytopenia in patients with malignant tumor
Author(s): TANG Yu, SHI Lin
Pages: 297-
299
Year: 2014
Issue:
5
Journal: New Chinese Medicine
Keyword: rhIL-11 derivatives; rhIL-11; Chemotherapy; Thrombocytopenia;
Abstract: Objective To evaluate the efficacy and side effect of rhIL-11 derivatives and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumor. Methods A total of 63 malignant tumor patients with grade Ⅲ-Ⅳ thrombocytopenia (≤50 ×1 09/L)after chemotherapy were collected and divided into treatment group and control group. At 24-48 hours after chemotherapy,the patients in treatment group received rhIL-11 derivatives 1.5 mg per day,while the patients in control group receive-drhIL-11 3 mg per day. The treatment would be ended when the platelets rose up to 1 00 ×1 09/L. The treat-ment time taken to get platelet rise up to 75 ×1 09/L or 1 00 ×1 09/L was compared between two groups. Ad-verse effects were observed during the treatment. Results There was a significant difference in the treatment time used to raise platelet up to 75 ×1 09/L between the treatment group (6.46 ±2.27)days and the control group (6.46 ±2.27)days (P<0.01 ). There was also a significant difference in the treatment time used to raise platelet up to 1 00 ×1 09/L between the treatment group (9.07 ±2.45 )days and the control group (11.59 ±2.78)days (P<0.01 ). The incidences of adverse effects between two groups showed no significant difference (P>0.05 ). Conclusion Bothe rhIL-11 derivatives and rhIL-11 are effective in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumor. The rhIL-11 derivatives has a more rapid effect to exhibit a slight advantage over rhIL-11.
Citations
No citation found
Related Articles
No related articles found